TLR9 and non-small cell lung carcinoma: It has been demonstrated that in non-small-cell lung cancer (NSCLC) cells, radiotherapy combined with TLR9 stimulation by the CpG ODN 7909 was able to downregulate PD-L1 (programmed death-ligand 1) expression which plays an important role in tumor immune escapes [47, 48].